Canada’s Drug Agency Launches Consultation on New Methods Guide for Health Technology Assessments

By João L. Carapinha

December 2, 2024

Canada’s Drug Agency launched a consultation on their first-ever methods guide. This methods guide is designed to describe the processes involved in conducting health technology assessments (HTAs) and appraising the clinical evidence for drugs submitted to the Drug Reimbursement Review program.

Purpose and Scope

The methods guide aims to clarify the procedures that the agency follows. It details how evidence is evaluated in relation to HTAs for drug reimbursement.

Consultation Details

The consultation period is open from November 28, 2024, to January 28, 2025. This 8-week timeframe allows for feedback from interested parties, including those who generate and submit evidence, as well as those who conduct the evidence appraisal.

Content of the Methods Guide

This guide incorporates leading methodological practices from HTA organizations both within Canada and internationally. It includes the evaluation of clinical and economic evidence, patient and clinician input, and ethical and implementation considerations.

Objectives

The primary goal of the methods guide is to enhance transparency in the agency’s processes and provide a clearer understanding of their work. The agency intends this to be a living document and will update it periodically based on scientific advancements and user feedback.

Application and Use

The methods guide is part of a suite of drug review guidance documents, which also includes:
– Guidelines for the Economic Evaluation of Health Technologies: Canada
– Guidance for Reporting Real-World Evidence.

Stakeholder Engagement

The consultation seeks extensive feedback from partners and interested parties to improve the methods guide. Partners and interested parties can submit feedback by downloading the draft document, completing the feedback form, and sending it to the specified email address by January 28, 2025.

Role in Drug Reimbursement

The HTA process conducted by Canada’s Drug Agency is critical for informing decisions about drug reimbursement and implementation. The agency’s expert committees utilize these evaluations to make recommendations to public drug programs and cancer agencies (excluding Quebec).

In summary, the consultation on the methods guide represents a significant effort by Canada’s Drug Agency to enhance transparency, incorporate best practices, and ensure that their evaluation processes for drug reimbursement are robust and evidence-based.

Reference url

Recent Posts

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

essential prescription drugs
       

Canada Launches Consultation for Essential Prescription Drugs List

💊 Are you curious about how Canada plans to make essential prescription drugs accessible for everyone?

Canada’s Drug Agency has launched a national consultation to create a list of essential prescriptions that aim to ensure equitable access, improve health outcomes, and reduce costs. This initiative marks a key step towards universal pharmacare and highlights the importance of evidence-based practices in healthcare.

Dive into our latest article to learn more about the implications for patients, policymakers, and the broader healthcare system!

#SyenzaNews #healthcare #HealthEconomics

ACIP vaccine policy concerns
     

ACIP Vaccine Policy Concerns

🛑 Is the future of vaccine policy at risk?

The recent overhaul of the US Advisory Committee on Immunization Practices (ACIP) raises critical concerns about the integrity and transparency in vaccine recommendations. The abrupt removal of longstanding members may disrupt the essential processes that have historically upheld public trust and immunization success.

Curious about the implications for health policy and public health? Dive into the full analysis to understand the balance needed between continuity and reform!

#SyenzaNews #HealthcarePolicy #HealthEconomics #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.